The global burden of disease study 2013: What does it mean for the NTDs?

Abstract

The Global Burden of Disease Study (GBD) is a landmark initiative that systematically quantifies the prevalence, morbidity, and mortality for hundreds of diseases, injuries, and risk factors of global health importance. For the neglected tropical diseases (NTDs), the GBD 2010 confirmed a high disease burden for the 17 major NTDs prioritized by the World Health Organization (WHO) as well as for selected conditions also recognized as NTDs by PLOS Neglected Tropical Diseases, including amoebiasis, cholera, cryptosporidiosis, typhoid and paratyphoid fevers, trichomoniasis, venomous animal contact, and scabies (referred to here as “additional NTDs”) [1]. The GBD 2013 is intended to be the first in a series of annual updates for the GBD studies, with its initial results published in 2015 in The Lancet [2–4]. Here, we review information on the NTDs published in the GBD 2013 capstone papers [2–4] and present new NTD data and updated burden estimates from the GBD 2013 study and new country-specific estimates. We show key outputs of GBD 2013 including country-specific estimates of prevalence or incidence and health-gap metrics for the aforementioned NTDs

Analysis of research intensity on infectious disease by disease burden reveals which infectious diseases are neglected by researchers

“…Another concern is that the DALYs might underestimate the burden of some diseases. For example, deaths from renal disease caused by schistosomiasis may have been placed in the renal disease category rather than the schistosomiasis category in DALYs, measured by the global burden of disease (22). This can be especially relevant when interpreting the high research intensity for diseases with a low disease burden, such as Chagas disease and leishmaniasis.…”

Counting Down the 2020 Goals for 9 Neglected Tropical Diseases: What Have We Learned From Quantitative Analysis and Transmission Modeling?

“…In support of these aspirations, a diverse consortium of donors, pharmaceutical companies, government agencies, and others made large commitments of funding, donated treatments, and other activities for 10 of these diseases in the London Declaration on NTDs [2]. Large morbidity gains have been made over recent years [3], and there are active discussions on how to exploit the likely synergies between the goals for NTDs and universal health coverage (UHC), a sustainable development goal (SDG; target 3.8) [4], in particular how to extend these gains to the hardest-to-reach or conflict-affected communities [5]. Of these 10 diseases, Guinea worm is targeted for eradication; the remaining 9 infections are targeted for elimination as a public health problem in some settings.…”

Development of a Focused Library of Triazole‐Linked Privileged‐Structure‐Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections

“…Infectious diseases caused by protozoan parasites pose a significant threat to human health, being responsible for more than a million deaths annually . They also blight the lives of millions of people worldwide, affecting both the health and economic stability of societies .…”

“…Infectious diseases caused by protozoan parasites pose as ignificant threat to human health, being responsible for more than am illiond eaths annually. [1] They also blight the lives of millions of people worldwide, affecting both the health and economic stability of societies. [2] Malaria,l eishmaniasis,a nd trypanosomiasisa re three of the most important human protozoan diseases in terms of morbidity and mortality.For them, disability-adjusted life years, that is,t he number of healthy life years lost to disability or premature death,i se stimated to be in the millions.…”